View Post

IMpassion130: PD-L1 Immune Cells Predictive of Survival Outcomes in Advanced TNBC

In Clinical Trials by Barbara Jacoby

By: Andrea S. Blevins Primeau, PhD, MBA From: cancertherapyadvisor.com PD-L1 tumor expression predicted survival outcomes among patients with advanced triple-negative breast cancer (TNBC) treated with atezolizumab plus nab-paclitaxel in the IMpassion130 study, according to data presented at the 2018 San Antonio Breast Cancer Symposium in Texas.1 It was previously reported that the phase 3 IMpassion130 trial (ClinicalTrials.gov Identifier: NCT02425891) met …

View Post

CAR-T Trial for Triple-Negative Breast Cancer Under Way

In Clinical Trials by Barbara Jacoby

By: Christina Bennett, MS From: cancertherapyadvisor.com A phase 1 trial (ClinicalTrials.gov Identifier: NCT02706392) is underway at Fred Hutchinson Cancer Research Center to evaluate a chimeric antigen receptor (CAR) T cell therapy in patients with cancer who have receptor tyrosine kinase-like orphan receptor 1 (ROR1)-positive disease, including those with triple-negative breast cancer (TNBC). The trial progress and early data for patients …

View Post

Syros Announces New Preclinical Data on SY-1365 at San Antonio Breast Cancer Symposium

In Clinical Trials by Barbara Jacoby

From: businesswire.com SY-1365 Shows Synergistic Activity in Combination with Fulvestrant in HR-Positive Breast Cancer Cells Resistant to Treatment with a CDK4/6 Inhibitor, Supporting Ongoing Clinical Investigation of the Combination Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) …

View Post

DNAtrix’s Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial

In Clinical Trials by Barbara Jacoby

Source: DNAtrix From: prnewswire.com DNAtrix, a leader in oncolytic virus immunotherapies for cancer, announced today the treatment of the first patient with DNX-2440, an oncolytic virus expressing OX40 ligand (OX40L). The first-in-human Phase 1 study is evaluating the safety and efficacy of DNX-2440, administered by Alcyone’s Microtip Cannula at the time of biopsy, to patients with recurrent glioblastoma for whom …

View Post

Legislature passes bill to improve access to cancer clinical trials

In Clinical Trials by Barbara Jacoby

From: dailylocal.com WEST CHESTER—A new law designed to improve access to clinical trials for Pennsylvanians battling cancer is heading to the governor’s desk, state Senator Andy Dinniman said. House Bill 126 unanimously passed the Pennsylvania Senate this week after receiving unanimous approval in the House earlier this year. The bill was amended to include language from Dinniman’s Senate Bill 576, …

View Post

Inovio Announces Initiation of “MD Anderson’s HPV-Related Cancers Moon Shot” Phase 2 Trial in New HPV Indications

In Clinical Trials by Barbara Jacoby

Source: Inovio Pharmaceuticals, Inc. From: globenewswire.com Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today the dosing of the first patient in a Phase 2 combination trial to evaluate MedImmune’s MEDI0457 (formerly called INO-3112 which MedImmune in-licensed from Inovio) in combination with durvalumab targeting a broad array of cancers associated with the human papilloma virus (HPV). This open-label trial funded by MedImmune, the …

View Post

NCI Supports Precision Medicine with Updated Clinical Trial Criteria

In Clinical Trials by Barbara Jacoby

By: Jessica Kent From: healthitanalytics.com The updated clinical trial criteria will broaden eligibility and participation in cancer trials, potentially leading to precision medicine breakthroughs. The National Cancer Institute (NCI) has revised its clinical trial protocol template to expand eligibility criteria for cancer clinical trials. The updated criteria will allow patients with certain health conditions to participate in NCI-funded trials, as …

View Post

Cancer drug from Kansas company can be tested on humans, FDA says. It’s made of lilies

In Clinical Trials by Barbara Jacoby

By: Lisa Gutierrez From: kansascity.com The Food and Drug Administration has approved human clinical testing for a new cancer drug created by a company based in the town of Sterling, Kansas — population 2,200, right in the middle of the state. The Genzada Pharmaceuticals drug is made from a flower native to the Middle East — described as “a black …

View Post

Cancer Research Highlight: Puma Biotech’s Basket Pays Off

In Clinical Trials by Barbara Jacoby

By: Zach Hartman From: seekingalpha.com Summary Puma Biotechnology is known almost exclusively as a breast cancer company. New basket study results may portend a move outside of there, but you have to think outside the box. How relevant are HER2 mutations, though? Puma Biotechnology (PBYI) has made its entire game up on the back of one drug, a “pan-HER” inhibitor …

View Post

New Report Charts Dramatic Growth in the Global Clinical Trial Landscape for PD-1/L1 Immune Checkpoint Inhibitors

In Clinical Trials by Barbara Jacoby

From: cancerresearch.org 2,250 clinical trials are evaluating PD-1/L1 immune checkpoint inhibitors, an increase of 748 trials over the past year 1,716 trials are assessing regimens that combine PD-1/L1 immune checkpoints with other cancer therapies 240 drug targets are being evaluated in the current landscape, 75 more targets compared to a year ago Over 380,000 patient volunteers are required to fill …